ALK-Abelló A/S (0OIR.IL)

153,50 +4,05 (+2,71%) In data: 10:07AM BST. Mercato aperto.

ALK-Abelló A/S

Boge Alle 6-8
Horsholm 2970
Denmark
45 45 74 75 76
https://www.alk.net

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2.727

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Carsten Hellmann	Pres, CEO & Member of Management Board	14,37M	N/D	1964
Mr. Søren Daniel Niegel	Exec. VP of Commercial Operations & Member of Management Board	5,8M	N/D	1971
Ms. Katja Barnkob Thalund	Project Director of Global CMC Devel. & Employee-elected Director	350k	N/D	1969
Mr. Claus Steensen Solje	Exec. VP, CFO & Member of Management Board	N/D	N/D	1962
Dr. Henriette Mersebach	Exec. VP R&D & Member of Management Board	N/D	N/D	N/D
Mr. Per Plotnikof	VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR	N/D	N/D	N/D
Prof. Hendrik Kees Kam Nolte M.D., Ph.D.	Sr. VP of Research & Devel. - North America and International Markets	N/D	N/D	N/D
Mr. Christian G. Houghton	Head of Product Supply	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Governance aziendale

L'ISS Governance QualityScore di ALK-Abelló A/S al 1 ottobre 2023 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 3; diritti degli azionisti: 10; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.